

STROBE statement: Reporting guidelines checklist for cohort, case-control and cross-sectional studies

SECTION	ITEM NUMBER	CHECKLIST ITEM	REPORTED ON PAGE NUMBER:
TITLE AND ABSTRACT			
	1a	Indicate the study's design with a commonly used term in the title or the abstract	3
	1b	Provide in the abstract an informative and balanced summary of what was done and what was found	3
INTRODUCTION			
Background and objectives	2	Explain the scientific background and rationale for the investigation being reported	4
	3	State specific objectives, including any pre-specified hypotheses	5
METHODS			
Study design	4	Present key elements of study design early in the paper	5
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	5
Participants	6a	Cohort study—Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up Case-control study—Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls Cross-sectional study—Give the eligibility criteria, and the sources and methods of selection of participants	5
	6b	Cohort study—For matched studies, give matching criteria and number of exposed and unexposed Case-control study—For matched studies, give matching criteria and the number of controls per case Variables	5
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	6,21; Supplementary material: supplementary Tables S1 and S2

SECTION	ITEM NUMBER	CHECKLIST ITEM	REPORTED ON PAGE NUMBER:
Data sources/measurements	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group.	6; Supplementary material: Study protocol
Bias	9	Describe any efforts to address potential sources of bias.	Supplementary material: Study protocol
Study size	10	Explain how the study size was arrived at	6
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why.	6,7; Supplementary material: Supplementary methods (pages 2-6)
Statistical methods	12a	Describe all statistical methods, including those used to control for confounding	6,7
	12b	Describe any methods used to examine subgroups and interactions	6
	12c	Explain how missing data were addressed	6,7
	12d	Cohort study—If applicable, explain how loss to follow-up was addressed Case-control study—If applicable, explain how matching of cases and controls was addressed Cross-sectional study—If applicable, describe analytical methods taking account of sampling strategy	5
	12e	Describe any sensitivity analyses	NA
RESULTS			
Participants	13a	Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	7
	13b	Give reasons for non-participation at each stage	7
	13c	Consider use of a flow diagram	19,20; Figure 1 as a separate file
Descriptive Data	14a	Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	7,8,21
	14b	Indicate number of participants with missing data for each variable of interest	NA

SECTION	ITEM NUMBER	CHECKLIST ITEM	REPORTED ON PAGE NUMBER:
	14c	Cohort study—Summarise follow-up time (eg, average and total amount)	NA
Outcome Data	15*	Cohort study—Report numbers of outcome events or summary measures over time Case-control study—Report numbers in each exposure category, or summary measures of exposure Cross-sectional study—Report numbers of outcome events or summary measures	NA 7-9, 22-24; Supplementary material: supplementary Tables S3-S6 (pages 6-26)
Main Results	16a	Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (e.g. 95% confidence interval). Make clear which confounders were adjusted for and why they were included	10,19,20; Figures 2,3 in a separate file
	16b	Report category boundaries when continuous variables were categorized	NA
	16c	If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	NA
	16d	Report results of any adjustments for multiple comparisons	NA
Other Analyses	17a	Report other analyses done—e.g. analyses of subgroups and interactions, and sensitivity analyses	Supplementary material: supplementary Table S4 (pages 9,10)
	17b	If numerous genetic exposures (genetic variants) were examined, summarize results from all analyses undertaken	NA
	17c	If detailed results are available elsewhere, state how they can be accessed	7 (Supplementary material)
DISCUSSION			
Key Results	18	Summarise key results with reference to study objectives	10,11
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	14
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	10-14

SECTION	ITEM NUMBER	CHECKLIST ITEM	REPORTED ON PAGE NUMBER:
Generalisability	21	Discuss the generalisability (external validity) of the study results Other information	14
FUNDING			
	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	15

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.